Perseus Proteomics : Notice on Booking of Non-operating Income, Non-operating Expenses, Extraordinary Income and Extraordinary Loss

February 14, 2022

Perseus Proteomics Inc.

Securities Code: 4882 Mothers TSE

To all stakeholders,

Notice on Booking of Non-operating Income, Non-operating Expenses, Extraordinary Income

and Extraordinary Loss

Perseus Proteomics Inc. (The Company) announces that the non-operating income, non-operating expenses, extraordinary income and the extraordinary loss were booked in the third quarter of the fiscal year ending March 31, 2022. The details are as follows:

1. Non-operating income

The Company has booked foreign exchange gains of 3,409 thousand yen and subsidy income of 234 thousand yen respectively, as non-operating income.

2. Non-operating expenses

The Company has booked listing expenses of 9,531 thousand yen including printing cost of prospectuses and handling fees related to public offering along with listing on Mothers Market TSE on June 22, 2021, as well as taxes and dues of 9,346 thousand yen incurred by payment for registration license tax, as non-operating expenses.

3. Extraordinary income

The Company has booked gain on reversal of share acquisition rights of 2,398 thousand yen with regards to the rights of which execution condition will no longer be established, as extraordinary income.

4. Extraordinary loss

The Company has booked impairment loss of 22,079 thousand yen for its noncurrent assets as an extraordinary loss in accordance with the Accounting Standard for Impairment of Fixed Assets.

5. Impact on financial results

There is no change in the financial results forecast of the fiscal year ending March 31, 2022 announced on June 22, 2021.

END